Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy

Japanese Journal of Clinical Oncology

Volumn 38, Issue 3, 2008, Pages 214-221

  Suzuki, Yasuhiro ^a   Tokuda, Yutaka ^a   Fujiwara, Yasuhiro ^b   Minami, Hironobu ^c   Ohashi, Yasuo ^d   Saijo, Nagahiro ^e  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c National Cancer Center Hospital East   (China)

^d UNIVERSITY OF TOKYO   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Anaemia; Cancer; Chemotherapy; Erythropoietin; Quality of life

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PLATINUM; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; BRAIN INFARCTION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FUNCTIONAL ASSESSMENT OF CANCER THERAPY ANEMIA QUESTIONNAIRE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LEUKOPENIA; LUNG CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RASH; SIDE EFFECT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; BLOOD; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; LUNG TUMOR; MIDDLE AGED; OVARY TUMOR; PATIENT COMPLIANCE;

ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PATIENT COMPLIANCE; QUALITY OF LIFE;

EID: 40749107443     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn002     Document Type: Article

References (20)

1. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapopert B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19(11):2865-74.
2. Demetri GD, Kris M, Wade J, Degos, L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998;16(10):3412-25.
3. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-34.
4. Demetri GD, Gabrilove JL, Blasi MV, Hill RJ, Glaspy JJ. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 2002;3(1):45-51.
5. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19(11):2875-82.
6. Morishima Y, Ogura M, Yoneda S, Sakai H, Tobinai Y, Nishiwaki Y, et al. Qnce-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study. Jpn J Clin Oncol 2006;36(10):655-61.
7. Yoshimura A, Kobayashi K, Fumimoto H, Fujiki Y, Eremenco S, Kudoh S. Cross-cultural validation of the Japanese Functional Assessment of Cancer Therapy-Anemia (FACT-An). J Nippon Med Sch 2004;71(5):314-22.
8. Kurita M, Shimozuma K, Morita S, Fujiki Y, Ishizawa K, Eguchi H, et al. Clinical validity of the Japanese version of the Functional Assessment of Cancer Therapy-Anemia Scale. Support Care Cancer 2007;15(1):1-6.
9. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-107.
10. Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP. Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial. J pain Symptom Manage 2003;25(6):512-8.
11. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences in the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue Scales. J Pain Symptom Manage 2002;24:547-61.
12. Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20(10):2486-94.
13. Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz HJ, Nortier JW. Epoetip alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2002;21(2):366-73.
14. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23(12):2606-17.
15. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122(3):394-403.
16. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23(12):2597-605.
17. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck-cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
18. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patiens with metastatic breast cancer receiving first line chemotherapy: A survival study. J Clin Oncol 2005;23(25):5960-72.
19. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98(10):708-14.
20. FDA ALERT [Updated 2007 Mar 09; cited 2006 Nov 16] Information on Erythropoiesis Stimulating Agents (ESA) available at http://www.fda.gov/ cder/drug/InfoSheets/HCP/RHE2007HCP.htm